12 May 2022 07:00
Yourgene Health plc
("Yourgene" or the "Company")
CEO share purchaseDirector/PDMR Shareholding
Manchester, UK - 12 May 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified 11 May 2022 that Lyn Rees, Chief Executive Officer of the Company, purchased 1,000,000 (1 million) ordinary shares on 11 May 2022 at a price of 7p per share in his SIPP account.
Following the above transaction, Lyn Rees is interested in 2,037,902 ordinary shares in the Company, representing approximately 0.3 per cent. of the Company's issued share capital.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.The Directors of the Company take responsibility for this announcement.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | |
Barry Hextall, Chief Financial Officer |
| |
Joanne Cross, Director of Marketing |
| |
|
| |
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |
Liam Murray / James Caithie / Ludovico Lazzaretti | ||
Singer Capital Markets (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | |
Aubrey Powell / Tom Salvesen / George Tzimas |
| |
|
| |
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |
Nicholas Moore / Matthew Blawat / Ben Maddison |
| |
|
| |
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / Mob: 07584 391 303 | |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Lyn Rees
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Yourgene Health plc | |||
b)
| LEI
| 213800UUIT8BZE7QEH33 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 0.1p each | |||
Identification code | ISIN: GB00BN31ZD89 | ||||
| |||||
b)
| Nature of the transaction
| Purchase of ordinary shares
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
7.1p | 1,000,000 | ||||
|
|
|
| ||
d)
| Aggregated information | N/A | |||
- Aggregated volume | |||||
- Price | |||||
e)
| Date of the transaction
| 11 May 2022 | |||
f)
| Place of the transaction
| UK | |||